The coating reported herein was found to have potentially favorable chemical and physical characteristics fostering osseointegration.
Objectives Burning mouth syndrome (BMS) is a medical entity characterised by a spontaneous sensation of burning, numbness or pain of the oral mucosa in the absence of clinical symptoms. The goal of this systematic review was to assess the efficacy of various current treatments for BMS. Methods The literature search used the following inclusion criteria: randomised controlled trials (RCTs) which compared one or more treatment strategies for patients with primary/idiopathic BMS with a placebo group describing all types of interventions. The primary and secondary outcome measures included: relief of pain/burning sensations, changes in psychosocial factors and feeling of sensation of dryness. A computer and manual search was performed in Pubmed, Web of Science and Cochrane Library up to 5 November 2019 and updated on 28 June 2020. The risk of bias was measured with the Cochrane Collaboration tool. Results Thirty RCTs which included 727 study participants and 589 controls were identified. The following interventions were introduced: dietary supplements, anticonvulsants, benzodiazepines, antidepressants, analgesics, topical agents, electromagnetic radiation or induction, physical barriers and psychological therapies. The most successful therapeutic outcomes were observed for clonazepam tested in 3 RCTs, where significant pain reduction appeared after both topical and systemic application. Evident pain reduction was also reported for tongue protectors and capsaicin in 2 separate studies. Discussion Short follow‐up periods, low numbers of participants, variability of the metrics used in the evaluation of the results and heterogeneous study design were the main limitations of the reviewed studies. Based on our analysis, clonazepam appears to be the most effective treatment option for BMS.
Background. A dental implant surface which would promote rapid and strong osseointegration is a key factor of success in modern implantology. To achieve this goal, different implant surface modifications are developed. A hydroxyapatite (HA) coating changing a bioinert titanium surface into bioactive is one of them. Objectives. The objective of the study was to investigate the effects on bone osseointegration in rabbits resulting from the application of a HA coating deposited on titanium endosseous implants using a modified electrochemical method. Material and methods. Titanium implants with HA coatings and controls with Al 2 O 3 grit-blasted surfaces were embedded into rabbit tibiae. The chemical composition, roughness and morphology of the implants were determined. Implant stability tests were performed, and the Periotest ® value (PTV) and the implant stability quotient (ISQ) value for Osstell Mentor were recorded in order to evaluate the osseointegration. Results. The surface characterization of the implants revealed a microstructure with an arithmetical mean height (Sa) in the range of 0.71-1.04 µm. The HA coating was free of contamination, whereas the controls were enriched with corundum. After healing, a statistically significant increase in the mean ISQ and a decrease in the mean PTV for the HA-coated implants was observed. In the case of the control implants, only PTV decreased significantly with time. Conclusions. The present study found that implant surface properties affected implant stability as determined by Osstell and Periotest measurements. The HA coating reported herein was found to have chemical and physical properties which appear to improve osseointegration compared to grit-blasted implants.
The goal of this systematic review was to assess the efficacy of dexamethasone compared to other treatments in oral lichen planus (OLP). The literature search used the following inclusion criteria: randomized controlled trials (RCT) comparing dexamethasone and other treatment strategies in patients with OLP. The outcome measures included relief of symptoms, decrement of erosive area size, and changes in quality of life. A computer and manual search was performed in Pubmed, Web of Science, and Cochrane Library up to January 31, 2021. The risk of bias was measured with the Revised Cochrane risk‐of‐bias tool for randomized trials. Eight trials with 131 study participants and 132 controls were identified. The following interventions were compared dexamethasone mouthwash, and 5% methylene blue‐mediated photodynamic therapy, low‐level laser therapy, amlexanox, clobetasol mouthwash, ketoconazole with amitriptyline, and thalidomide 1% paste. The therapeutic outcomes were more advantageous for dexamethasone in comparison with photodynamic therapy (PDT) (2 RCT) and low‐level laser therapy (LLLT). Comparable effects were observed for dexamethasone, amlexanox, thalidomide, and PDT (1 RCT). Clobetasol showed more effective action than dexamethasone. Given the small sample sizes, heterogeneity and the few studies included, there is limited evidence to support the selection of treatment for OLP.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.